Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition

✍ Scribed by Jens Selige; Hermann Tenor; Armin Hatzelmann; Torsten Dunkern

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 368 KB
• Volume: 223
• Category: Article
• ISSN: 0021-9541
• DOI: 10.1002/jcp.22037

✦ Synopsis

Abstract

Interleukin‐1β (IL‐1β) and basic fibroblast growth factor (bFGF) are important regulators of proliferation, and their expression is increased in lungs of patients with asthma, idiopathic pulmonary fibrosis (IPF), or chronic obstructive pulmonary disease (COPD). We investigated the effect of IL‐1β and bFGF on proliferation of human lung fibroblasts and the role of COX‐2, PGE~2~, and cAMP in this process. Furthermore, the effect of phosphodiesterase (PDE) 3 and 4 inhibition was analyzed. In primary human lung fibroblasts low concentrations of IL‐1β (<10 pg/ml) potentiated the bFGF‐induced DNA synthesis, whereas higher concentrations revealed antiproliferative effects. Higher concentrations of IL‐1β‐induced COX‐2 mRNA and protein associated with an increase in PGE~2~ and cAMP, and all of these parameters were potentiated by bFGF. The PDE4 inhibitor piclamilast concentration‐dependently reduced proliferation by a partial G1 arrest. The PDE3 inhibitor motapizone was inactive by itself but enhanced the effect of the PDE4 inhibitor. This study demonstrates that bFGF and IL‐1β act in concert to fine‐tune lung fibroblast proliferation resulting in amplification or reduction. The antiproliferative effect of IL‐1β is likely attributed to the induction of COX‐2, which is further potentiated by bFGF, and the subsequent generation of PGE~2~ and cAMP. Inhibition of PDE4 inhibition (rather than PDE3) may diminish proliferation of human lung fibroblasts and therefore could be useful in the therapy of pathological remodeling in lung diseases. J. Cell. Physiol. 223: 317–326, 2010. © 2010 Wiley‐Liss, Inc.